Patient-reported outcome measures for allergy and asthma in children

Ireneous N Soyiri1, Bright I Nwaru1,2, Aziz Sheikh1

  • 1Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.

Insights

Patient-reported outcome measures (PROMs) are vital for assessing pediatric allergies and asthma. While validated tools exist, more research is needed on their use in routine clinical care.

Area of Science:

  • Pediatric Allergy and Immunology
  • Clinical Outcomes Research

Background:

  • Patient perceptions of disease and healthcare are increasingly recognized as crucial, comparable to traditional objective measures.
  • Patient-reported outcome measures (PROMs) capture these subjective experiences, offering unique insights, especially for pediatric populations.
  • For minors, both parental and child perspectives are vital, providing complementary information to objective assessments.

Purpose of the Study:

  • To review and summarize existing evidence on patient-reported outcome measures (PROMs) for allergy and asthma in children.
  • To identify validated pediatric PROMs for specific allergic conditions and asthma.
  • To highlight the need for research on the implementation and utility of these PROMs in routine clinical practice.

Main Methods:

  • Systematic review of literature on pediatric PROMs for allergy and asthma.
  • Identification and evaluation of validated instruments for conditions including atopic eczema, food allergy, allergic rhinitis, and asthma.
  • Assessment of evidence regarding the deployment of these PROMs outside of research settings.

Main Results:

  • Fewer validated PROMs are available for pediatric use compared to adults.
  • Validated pediatric PROMs were identified for atopic eczema/dermatitis, food allergy, allergic rhinitis/rhinoconjunctivitis, and asthma.
  • Evidence on the use of these PROMs in routine clinical settings is very limited.

Conclusions:

  • There is a pressing need to report on the experiences of using PROMs for pediatric allergy and asthma in routine clinical care.
  • Further research should focus on the acceptability, integration into clinical workflows, and responsiveness of pediatric PROMs to treatment changes.
  • Understanding these aspects is crucial for effectively incorporating PROMs into standard pediatric allergy and asthma management.

Related Concept Videos

Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.6K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.7K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.8K